About 18 months after forcibly defending the viability of conducting R&D on RNA-interference therapeutics, Alnylam Pharmaceuticals Inc. CEO John Maraganore remains on the job but is sitting in a different place.
The decision by Rochein late 2010to exit RNAi drug development and its longstanding collaboration with Alnylam, just months after Novartis AG and Pfizer Inc. also left the field, turned the fortunes of the Cambridge, Mass
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?